Harvard Bioscience (HBIO) Reports Flat Q2 EPS; Maintains FY08 Outlook
More News related to HBIO
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Harvard Bioscience (HBIO) Appoints McNaughton New CFO
- Harvard Bioscience (HBIO) Reports Flat Q2 EPS; Maintains FY08 Outlook
- Harvard Bioscience (HBIO) Tops Q4 EPS by 2c, Guides for Q1 and FY08
- Harvard Bioscience (HBIO) Rejects Skystone Buyout Offer
Harvard Bioscience, Inc. (Nasdaq: HBIO) reports Q2 non-GAAP EPS of $0.08, versus $0.08 reported in Q207. Revenues for the quarter were $23 million, compared to $20.4 million in the same quarter last year.
Maintains its FY08 non-GAAP EPS of $0.36-$0.38 and $94-$96 million in sales.
Harvard Bioscience, Inc. develops, distributes, manufactures, and markets apparatus and scientific instruments used in life science research at pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
